Niox Group PLC banner

Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 59.4 GBX -1% Market Closed
Market Cap: £248.3m

Niox Group PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Niox Group PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
EPS (Diluted)
£0
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
EPS (Diluted)
-$2
CAGR 3-Years
26%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
EPS (Diluted)
£0
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
EPS (Diluted)
-$2
CAGR 3-Years
-9%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
EPS (Diluted)
£0
CAGR 3-Years
11%
CAGR 5-Years
1%
CAGR 10-Years
4%
Oxford BioMedica PLC
LSE:OXB
EPS (Diluted)
£0
CAGR 3-Years
-10%
CAGR 5-Years
-17%
CAGR 10-Years
-6%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
248.3m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
49.1 GBX
Overvaluation 17%
Intrinsic Value
Price

See Also

What is Niox Group PLC's EPS (Diluted)?
EPS (Diluted)
0 GBP

Based on the financial report for Jun 30, 2025, Niox Group PLC's EPS (Diluted) amounts to 0 GBP.

What is Niox Group PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-31%

Over the last year, the EPS (Diluted) growth was -50%. The average annual EPS (Diluted) growth rates for Niox Group PLC have been -31% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett